Rifampin Pediatric Dose — Antimicrobial Reference
Rifampin is a rifamycin-class antimicrobial that inhibits bacterial DNA-dependent RNA polymerase, disrupting RNA synthesis. It is used in pediatric practice primarily for the treatment and prophylaxis of mycobacterial infections, meningococcal and Haemophilus influenzae type b exposure prophylaxis, and as adjunctive therapy in select staphylococcal infections. Its broad activity and ability to penetrate biofilms and intracellular compartments make it a valuable component of combination antimicrobial regimens.
Pediatric Dosing
- Dose: 10 mg/kg/dose IV or PO every 12 hours
- Adult/maximum dose: 300 mg IV/PO every 12 hours
Doses should not exceed the adult dose of 300 mg per administration. For a 20 kg child: 20 × 10 mg/kg = 200 mg per dose every 12 hours. For a 35 kg child: 35 × 10 mg/kg = 350 mg, capped at 300 mg per dose every 12 hours. Consult institutional protocol for weight-based dosing adjustments in neonates or patients with hepatic impairment.
Indications and Clinical Context
Rifampin is indicated as a component of multi-drug regimens for tuberculosis and other mycobacterial infections in pediatric patients. It is also used for chemoprophylaxis following close contact with invasive meningococcal disease or H. influenzae type b disease, where short-course rifampin effectively eliminates nasopharyngeal carriage. In selected cases of prosthetic device or biofilm-associated staphylococcal infections, rifampin may be added as adjunctive therapy in combination with another active agent to prevent the emergence of resistance.
Because rifampin monotherapy rapidly selects for resistant mutants, it is virtually always prescribed as part of a combination regimen. Clinicians should confirm susceptibility data and consult infectious disease specialists for complex or prolonged courses.
Administration and Monitoring
Rifampin may be administered intravenously or orally. The IV formulation should be infused over 30 minutes when given parenterally. The oral formulation is preferably taken on an empty stomach to maximize absorption, though it may be given with food if gastrointestinal intolerance occurs. Rifampin is a potent inducer of hepatic cytochrome P450 enzymes (CYP3A4, CYP2C9, and others), resulting in clinically significant drug interactions; review the patient’s full medication list prior to initiation.
- Monitoring: Baseline and periodic liver function tests; monitor for hepatotoxicity, especially with concurrent hepatotoxic agents
- Adverse effects: Orange-red discoloration of urine, tears, and secretions (benign; counsel patients/families); GI upset; rash; thrombocytopenia
- Contraindications: Hypersensitivity to rifamycins; concurrent use with certain antiretrovirals or other drugs with narrow therapeutic indices may require dose modification or alternative selection — consult institutional protocol
- Drug interactions: Rifampin significantly reduces serum concentrations of many co-administered drugs; a comprehensive interaction check is essential before prescribing
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.